V. Georgoulias

1.3k total citations
38 papers, 1.0k citations indexed

About

V. Georgoulias is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, V. Georgoulias has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Dermatology. Recurrent topics in V. Georgoulias's work include Cancer Treatment and Pharmacology (15 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). V. Georgoulias is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Lung Cancer Research Studies (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). V. Georgoulias collaborates with scholars based in Greece and United States. V. Georgoulias's co-authors include D. Mavroudis, S. Kakolyris, Ch. Kouroussis, Ioannis G. Vlachonikolis, Stella Apostolaki, Maria Perraki, Aliki Stathopoulou, N. Malamos, Αthanasios Kotsakis and John Souglakos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

V. Georgoulias

38 papers receiving 980 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Georgoulias Greece	16	843	375	275	267	177	38	1.0k
Nahomi Tokudome Japan	18	980 1.2×	374 1.0×	206 0.7×	422 1.6×	63 0.4×	52	1.2k
Tina E. Wood United States	7	900 1.1×	331 0.9×	266 1.0×	218 0.8×	188 1.1×	12	1.1k
Karl Reinhard Aigner Germany	14	482 0.6×	225 0.6×	438 1.6×	192 0.7×	65 0.4×	63	946
J. L. Abbruzzese United States	17	636 0.8×	173 0.5×	309 1.1×	174 0.7×	126 0.7×	51	905
Su Hwan Kang South Korea	14	452 0.5×	358 1.0×	226 0.8×	160 0.6×	55 0.3×	59	842
Karwan Moutasim United Kingdom	17	455 0.5×	275 0.7×	440 1.6×	193 0.7×	43 0.2×	35	1.0k
Tsung‐Yen Cheng Taiwan	16	378 0.4×	130 0.3×	264 1.0×	133 0.5×	110 0.6×	20	723
Françoise Drusch France	14	544 0.6×	305 0.8×	215 0.8×	195 0.7×	74 0.4×	17	924
Yoshiatsu Sagara Japan	14	484 0.6×	337 0.9×	246 0.9×	101 0.4×	114 0.6×	26	804
Xuxia Shen China	21	365 0.4×	218 0.6×	319 1.2×	583 2.2×	128 0.7×	51	1.1k

Countries citing papers authored by V. Georgoulias

Since Specialization

Citations

This map shows the geographic impact of V. Georgoulias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Georgoulias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Georgoulias more than expected).

Fields of papers citing papers by V. Georgoulias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Georgoulias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Georgoulias. The network helps show where V. Georgoulias may publish in the future.

Co-authorship network of co-authors of V. Georgoulias

This figure shows the co-authorship network connecting the top 25 collaborators of V. Georgoulias. A scholar is included among the top collaborators of V. Georgoulias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Georgoulias. V. Georgoulias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sfakianaki, Maria, Chara Papadaki, Maria Tzardi, et al.. (2019). PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer. Annals of Oncology. 30. iv21–iv22. 9 indexed citations

Economopoulou, Panagiota, Leonidas Chelis, Aris Polyzos, et al.. (2016). Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Clinical & Translational Oncology. 19(3). 317–325. 7 indexed citations

Karachaliou, Niki, Ch. Kouroussis, Pavlos Papakotoulas, et al.. (2012). A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 69(5). 1345–1352. 2 indexed citations

Papadaki, Chara, Zacharenia Saridaki, Maria Sfakianaki, et al.. (2011). PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 434–434. 2 indexed citations

Valachis, Antonis, Nikolaos P. Polyzos, V. Georgoulias, Dimitris Mavroudis, & Davide Mauri. (2010). Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecologic Oncology. 117(1). 139–145. 29 indexed citations

Xenidis, Nikolaos, Αthanasios Kotsakis, A. Kalykaki, et al.. (2009). Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Lung Cancer. 68(3). 450–454. 5 indexed citations

Kakolyris, S., Athina Agelidou, N. Androulakis, et al.. (2006). Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma. Lung Cancer. 53(1). 59–65. 7 indexed citations

Mavroudis, D., Nikolaos Malamos, Aris Polyzos, et al.. (2004). Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology. 67(3-4). 250–256. 24 indexed citations

Kakolyris, Stylianos, John Souglakos, Ch. Kouroussis, et al.. (2004). Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors. Oncology. 66(4). 253–259. 2 indexed citations

10.

Mavroudis, D., Periklis Pappas, Ch. Kouroussis, et al.. (2003). A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Annals of Oncology. 14(2). 304–312. 32 indexed citations

11.

Xenidis, Nikolaos, Ioannis G. Vlachonikolis, D. Mavroudis, et al.. (2003). Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Annals of Oncology. 14(6). 849–855. 88 indexed citations

12.

Mavroudis, D., A. Alexopoulos, Nikolaos Malamos, et al.. (2003). Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin. Oncology. 64(3). 207–212. 17 indexed citations

13.

Mavroudis, D., M. Veslemes, F Apostolopoulou, et al.. (2002). Sequential administration of cisplatin–etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Lung Cancer. 39(1). 71–76. 11 indexed citations

14.

Mavroudis, D., Ch. Kouroussis, S. Kakolyris, et al.. (2002). Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors. Oncology. 62(3). 216–222. 29 indexed citations

15.

Kakolyris, S., Dimitriοs Mavroudis, John Souglakos, et al.. (2001). Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study. Annals of Oncology. 12(2). 193–198. 40 indexed citations

16.

Agelaki, Sofia, A. Alexopoulos, Charalambos Kouroussis, et al.. (2001). Salvage treatment with irinotecan and gemcitabine in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. European Journal of Cancer. 37. S197–S198. 1 indexed citations

17.

Mavroudis, Dimitriοs, E. Papadakis, M. Veslemes, et al.. (2001). A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancer. Annals of Oncology. 12(4). 463–470. 108 indexed citations

18.

Kouroussis, Ch., Sofia Agelaki, D. Mavroudis, et al.. (2000). A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 46(6). 488–492. 21 indexed citations

19.

Mavroudis, Dimitriοs, E. Papadakis, M. Veslemes, et al.. (1999). Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial. European Journal of Cancer. 35. S247–S247. 2 indexed citations

20.

Kakolyris, S., Charalambos Kouroussis, John Souglakos, et al.. (1998). Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 21. S32–S32. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact